Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised induction and post-induction therapy in older patients with AML or RAEB
2004-001918-13Phase 3Unknown
- Sponsor
- Cardiff University
- Start
- Jul 2005
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemtuzumab ozogamicin and daunorubicin in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB), sponsored by Cardiff University. Primary endpoint: Complete remission rate. Status: unknown.
02
Drugs
gemtuzumab ozogamicindaunorubicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on 2004-001918-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001918-13.